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Abstract. Background/Aim: We detected microRNA-7 (miR-
7) as being specific for oesophageal squamous cell
carcinoma (ESCC) by using database analysis. However, the
significance of miR-7 in clinical ESCC remains unexplored.
This study aimed to clarify the clinicopathological
significance of miR-7 in ESCC, and investigate miR-7
function. Materials and Methods: Quantitative TaqMan
reverse transcription polymerase chain reaction was used to
evaluate miR-7 expression in 85 ESCC samples to determine
the clinicopathological significance of miR-7 expression. The
regulation of proliferation by miR-7 was examined with miR-
7 precursor-transfected cells. Results: The expression of
miR-7 in ESCC was higher than that in normal tissues. Low
expression levels of miR-7 were associated with poor
prognosis. Multivariate analysis indicated that low miR-7
expression was an independent prognostic factor for poor
survival. In vitro assays showed miR-7 precursor treatment
suppressed the proliferation of ESCC cells. Conclusion: In
ESCC, miR-7 might be a promising prognostic marker and
therapeutic target. 
Survival of patients with advanced oesophageal squamous cell
carcinoma (ESCC) remains poor regardless of improvements
in perioperative management and definitive and adjuvant
therapy (1-3). Locally advanced ESCC directly invades
adjacent organs; this increases local recurrence and makes
radical surgical resection difficult. Moreover, such ESCC
cases exhibit early lymphatic and frequent haematogenous
dissemination compared with other types of gastrointestinal
cancer (4, 5). Therefore, markers that can predict ESCC
progression and prognosis correctly and reliably are needed
for improving survival of patients with ESCC.
MicroRNAs (miRs) have attracted attention as important
regulators of gene expression. These small non-coding RNAs
are 18-25 nucleotides in length and partially bind to the 3’-
untranslated region of target mRNAs. This binding of miR
and mRNA leads to mRNA degradation or translational
repression (6). Depending on their targets, many miRs play
important roles in proliferation, apoptosis, differentiation,
and cancer progression. In order to find cancer-specific miRs
in ESCC, we re-analysed data with the series accession
number GSE6188 in the Gene Expression Omnibus public
microarray database (7). As a result, we detected miR-196a,
miR-7, and miR-503 as being up-regulated by 6.64-, 4.31-
and 3.65-fold, respectively, in ESCC compared with normal
oesophageal mucosa. The function and expression
significance of miR-196a and miR-503 in ESCC have been
reported (8-10). In addition, Fu et al. reported that the
expression level of miR-7 in primary ESCC tissue was higher
than that in non-cancerous tissues (11), and Dong et al.
described serum miR-7 expression in patients with ESCC as
being higher than that in healthy volunteers (12). However,
few studies are available on the significance and function of
miR-7 expression in ESCC. 
The purpose of this study was to clarify the
clinicopathological significance of miR-7 expression in
ESCC, and to investigate the function of miR-7 in ESCC cells
in vitro. Therefore, we examined the expression of miR-7 in
clinical ESCC samples and the miR-7-mediated regulation of
proliferation in ESCC cells in vitro.
Materials and Methods
Cancer specific miR detection by re-analysis of GSE6188. Re-
analysis for GSE6188 was performed by Subio Platform (Subio Inc.
Tokyo, Japan). Probes significantly different between cancerous
tissues (153 samples) and normal tissues (104 samples) were
extracted with a fold-change greater than 3.5 and a t-test (equal
variance) with p<0.05. The probes corresponding to over half of 48
donors with two cancerous tissues and two adjacent normal tissues
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and whose clinical characteristics were significantly different were
selected as the three up-regulated miRs.
Clinical samples and RNA isolation. Samples of primary ESCC (n=85)
and corresponding normal oesophageal epithelium (n=85) were
obtained from patients with ESCC who had undergone potentially
curative surgery at the Department of General Surgical Science,
Gunma University, Japan, between 1999 and 2006. These samples
were used after obtaining written informed consent in accordance with
institutional guidelines and the Declaration of Helsinki (approval
number 1457). The pathological features of the samples were classified
according to the sixth edition of the TNM Classification of the
International Union against Cancer (13). The surgical procedures were
classified as curative; there was no evidence of residual tumour tissue,
and the resected margins were microscopically free of tumour (R0).
Normal tissue samples were obtained away from the centre of the
tumour in surgical specimens. All samples were immediately frozen
in liquid nitrogen and stored at −80˚C until RNA extraction. Total
RNA was extracted using the miRNeasy Mini kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. 
Evaluation of miR-7 expression in clinical ESCC samples. For
quantitative real-time reverse transcriptase–polymerase chain
reaction (RT-PCR) of miR-7, cDNA was synthesized from 10 ng
total RNA using the TaqMan MicroRNA Reverse Transcription kit
and specific stem-loop reverse transcription primers (Applied
Biosystems, Foster city, CA, USA) according to the manufacturer’s
protocol. PCR was performed in a LightCycler™ 480 system
(Roche Diagnostics GmbH, Mannheim, Germany). The 20 μl PCR
mixture included in the LightCycler 480 Probes Master kit (Roche
Diagnostics GmbH, Mannheim, Germany) was incubated in a 96-
well optical plate at 95˚C for 10 minutes, and then subjected to 45
cycles of 95˚C for 10 seconds and 60˚C for 30 seconds. Expression
levels of miR-7 were normalized to that of the small nuclear RNA
RNU6B and analysed using the 2–ΔΔCt method.
Cell line. The human ESCC cell line TE-8 was obtained from the
RIKEN BioResource Center (RIKEN BRC, Tukuba, Ibaraki, Japan).
TE-8 cells were cultured in RPMI_1640 medium (Wako, Osaka,
Japan) supplemented with 10% foetal bovine serum and 1%
penicillin–streptomycin antibiotics (Invitrogen, Carlsbad, CA, USA). 
Transfection of the miR-7 precursor. Pre-miR™ miRNA Precursor
Molecule mimicking miR-7 (premiR-7; Applied Biosystems) or non-
specific control miR (Pre-miR™ miRNA Negative Control #1;
premiR-nc; Applied Biosystems) was transfected at 30 pmol/l into
TE-8 cells by using an electroporator (CUY 21 EDIT II; BEX,
Tokyo, Japan) according to protocol. Before conducting assays, we
confirmed that miR-7 expression in premiR-7 precursor-treated cells
was significantly higher than that in the parent TE-8 cells and
control miR-treated cells using RT-PCR.
Proliferation assay. Cell proliferation analysis was performed using
cells that had been transfected with negative control or premiR-7.
The cells were plated in 96-well plates in 100 μl of medium at
approximately 3,000 cells per well. For the quantification of cell
viability in the WST-8 assay (Dojindo Lab., Tokyo, Japan), 10 μl of
the cell counting solution was added to each well after 0, 24, 48,
and 72 hours and plates were incubated at 37˚C for another 2 hours.
The cell proliferation rate was then determined by measuring the
absorbance of the well at 450 nm with the reference wavelength set
at 650 nm. Absorbance was read using a microtitre plate reader
(Molecular Devices, Sunnyvale, CA, USA). 
Statistical analysis. Differences between groups were estimated
using Student’s t-test, the chi-square test, and the repeated measures
ANOVA. Kaplan–Meier curves were generated for overall survival,
and statistical significance was determined using the log-rank test.
A probability value of less than 0.05 was considered significant. All
statistical analyses were performed using JMP software (SAS
Institute, Cary, NC, USA).
Results 
Clinical significance of miR-7 expression in patients with
ESCC. Re-analysis of GSE6188 revealed miR-196a, miR-7 and
miR-503 to be up-regulated in ESCC Among them, we focused
on miR-7 (Figure 1) in order to clarify the clinical significance
of miR-7 expression in clinical ESCC samples. We assessed
miR-7 expression in 85 ESCC samples and 85 paired non-
cancerous samples. The expression of miR-7 was significantly
greater in tumour than in normal tissue (p<0.001) (Figure 2A).
We divided the 85 patients with ESCC into two groups
according to the tumour/normal tissue ratio (T/N) for miR-7
expression, and the cut-off point was defined as T/N=8.5
(high-expression group, T/N≥8.5, n=31; low-expression
group, T/N<8.5, n=54). Clinicopathological factors did not
differ between the miR-7 low-expression and high-expression
groups (Table I). 
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Figure 1. Clinical significance of miR-7 expression in oesophageal
squamous cell carcinoma (ESCC) samples from the re-analysed
GSE6188 data. miR-7 levels were shown to be higher in ESCC than
those of the adjacent normal tissues.
Prognostic significance of miR-7 expression in patients with
ESCC. The overall survival curve revealed that the patients
in the low miR-7 expression group had a significantly poorer
prognosis than those in the high expression group (p=0.048)
(Figure 2B). In univariate and multivariate analyses, low
expression of miR-7 in ESCC was found to be a significant
independent prognostic factor (Table II). In multivariate
analysis, other investigated clinicopathological factors were
not revealed as significant independent predictors of poor
prognosis in this ESCC cohort, whereas low expression of
miR-7 in primary ESCC remained prognostically significant
with regard to overall survival.
Regulation of proliferation by miR-7 in ESCC cells. We
confirmed that the expression of miR-7 in miR-7 precursor-
transfected cells was higher than that in control cells (Figure
3A). Proliferation of miR-7 precursor-transfected cells was
significantly reduced from 48 h compared with control cells
(p<0.05) (Figure 3B).
Discussion
In this study, we clarified that a low expression level of miR-7
in ESCC was an independent prognostic factor in spite of
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Figure 2. miR-7 expression in 85 oesophageal squamous cell carcinoma
(ESCC) samples of our cohort and its relationship with survival. A: The
expression levels of miR-7 in tumour (T) and normal (N) tissue. Overall
(B) and disease-free (C) survival curves of patients with ESCC
according to miR-7 expression using a cut-off of 8.5.
Table I. Relationship between miR-7 expression and clinicopathological
features.
                                                         miR-7/RNU6B
Factors                              Low expression   High expression   p-Value
                                                 n=54                      n=31                   
Age                                                                                                      
   <65 Years                                 22                          14                  0.72 
   ≥65 Years                                 26                          14                          
Gender                                                                                                     
   Male                                         47                          29                  0.34 
   Female                                       7                            2                          
T Factor                                                                                                   
   T1                                             12                            7                  0.96 
   T2, T3, T4                               42                          24                          
N Factor                                                                                                  
   Absent                                      17                          10                  0.94 
   Present                                     37                          21                          
Lymphatic invasion                                                                                
   Absent                                        5                            1                  0.29 
   Present                                     49                          30                          
Venous invasion                                                                                      
   Absent                                        8                            8                  0.21 
   Present                                     46                          23                          
M Factor                                                                                                  
   Absent                                      44                          26                  0.78 
   Present                                     10                            5                          
Stage                                                                                               0.43 
   1                                                 8                            3                          
   2                                               15                          14                          
   3                                               20                            9                          
   4                                                11                            5                    
cancer-specific high expression and weak association with
increasing severity of clinicopathological factors. On in vitro
analysis, we found that the proliferation of miR-7 precursor-
treated ESCC cells decreased compared with the control cells. 
We focused on miR-7 as an ESCC-specific miR, and initially
predicted that miR-7 might function as a tumour promoter in
ESCC. The expression of miR-7 was found to be increased in
ESCC compared with normal tissue; however, patients with
ESCC with low miR-7 had a poorer prognosis than those with
high expression of miR-7. Similar to our findings in ESCC,
previous study revealed that miR-7 expression in colorectal
cancer cells was higher than that in normal cells but that the
prognosis was worse in the patients with low expression than
in those with high expression (14). On the other hand, down-
regulation of miR-7 expression has been described in thyroid
cancer and mesothelioma (15, 16). The detailed mechanism of
miR-7 regulation in ESCC is unclear; however, other
researchers have reported that E2F transcription factors
regulate miR-7 expression (17) and that USP18 negatively
regulate miR-7 expression (18). Moreover, Chuo et al. reported
that the activation of epidermal growth factor receptor (EGFR)
in lung cancer cells stimulated miR-7 expression via
extracellular signal-regulated kinase (19). E2F and EGFR have
been reported to be expressed in ESCC (20, 21); this suggests
that miR-7 might be at least partially regulated by the activation
of cancer-specific signals such as E2F and EGFR. 
Down-regulation of miR-7 in ESCC samples was not
associated with progression of existing clinicopathological
ANTICANCER RESEARCH 37: xxx-xxx (2017)
4
Figure 3. Proliferation potency of miR-7 precursor-transfected cells. A: Expression of miR-7 was shown to be significantly increased in miR-7
precursor-treated cells. B:The proliferation rate was reduced in miR-7 precursor-treated cells in comparison with that of control miR-treated cells.
The data represent the mean±SD. *Significantly different at p<0.05. 
Table II. Results of univariate and multivariate analyses of clinicopathological Factors affecting the overall survival rate following surgery.
Clinicopathologic variable                                                            Univariate analysis                                                    Multivariate analysis
                                                                                       RR                    95% CI                 p-Value                  RR                  95% CI                 p-Value
T Factor (T1/T2, T3, T4)                                             0.4                    0.15-0.89                0.022*                  0.57                  0.2-1.33                  0.204
N Factor (negative/positive)                                        0.4                    0.19-0.87                0.019*                  0.6                    0.25-1.3                  0.205
M Factor (negative/positive)                                        0.6                    0.29-1.25                0.157                    0.88                  0.42-2.0                  0.76
Lymphatic invasion (negative/positive)                      0.21                 0.01-0.99                0.0489*                0.4                    0.01-3.4                  0.428
Venous invasion (negative/positive)                            0.46                 0.15-1.08                0.0789                  0.98                  0.28-2.6                  0.969
miR-7 expression (high/low)                                        0.5                    0.23-0.97                0.0426*                0.48                 0.18-0.86                 0.0389*
RR: Relative risk, CI: confidence interval, *p<0.05.
factors; however, patients with miR-7 down-regulation had
poorer prognosis than those with high miR-7 expression.
miR-7 was reported to be suppressed in chemotherapy-
resistant cancer cells (22-24). Moreover, Lee et al. described
that miR-7 induction suppressed EGFR and protein kinase B
expression, and induced increased sensitivity to radiation
treatment in several cancer cell lines (25). Multiple targets
have been identified for miR-7, including EGFR, human
epidermal growth factor receptor 2, Raf-1 proto-oncogene,
multidrug resistance-associated protein 1, focal adhesion
kinase, insulin-like growth factor 1 receptor, B-cell
lymphoma 2, and SATB homeobox1, which are associated
with therapeutic resistance and malignant potential in several
cancer types (14, 23, 26-30). In this study, we found that
miR-7 precursor treatment suppressed cell growth by ESCC
cells. From these observations, we suggest that miR-7
induction in patients with ESCC might be useful as a
therapeutic strategy to overcome resistance to chemotherapy
or radiation therapy, which are very important therapeutic
tools for patients with ESCC.
In this study, we showed that miR-7 treatment induced an
anticancer effect on ESCC cells in vitro. This finding
indicates that administration of miR-7 to patients with ESCC
might be a useful means of attacking the ESCC cells. In fact,
previous reports have demonstrated that small RNAs
administered systemically to humans were able to inhibit
specific genes via an RNA interference mechanism, and
these therapeutic strategies have attracted attention (31-35).
Currently, the role of miR-7 in the human circulatory system
is not well understood; however, it has been reported that
high levels of serum miR-7 were associated with high
sensitivity to chemoradiation in patients with ESCC (12).
Administration of miR-7 to the circulation might function as
a sensitizer to chemotherapy or radiation therapy. In future,
determination of an effective means to deliver miRs to
cancerous tissue is an important task.
In conclusion, our data indicate that down-regulation of
miR-7 is associated with poor prognosis and reduced
proliferative ability in ESCC. The level of miR-7 in ESCC
might be a powerful prognostic factor independent of
existing clinicopathological factors. The regulation of miR-
7 could provide a promising novel possibility for targeted
therapeutic strategies in ESCC.
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